Addition of inhaled corticosteroids to long-acting β2-agonists does not improve outcomes in stable COPD

Aaron, Shawn D.
March 2010
ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p4
Academic Journal
The article focuses on a medical research related to effectiveness and safety of inhaled corticosteroids and long-acting β2-agonists (LABA) combined therapy in patients with stable chronic obstructive pulmonary disease (COPD). Combined LABA/ICS therapy reduced risk for moderate COPD exacerbations in comparison of LABA alone and increased the risk of Risks for pneumonia and viral respiratory infections. Combined LABA/ICS therapy is not more effective than LABAs alone.


Related Articles

  • COPD: Long-acting beta agonists canter survival benefit in older patients.  // Medical Economics;6/10/2011, Vol. 88 Issue 11, p65 

    The article focuses on the result of a study which confirms the survival advantage of long-acting beta agonists for treatment of chronic obstructive pulmonary diseases (COPD) in older patients.

  • Salmeterol/fluticasone use yields savings in COPD.  // PharmacoEconomics & Outcomes News;6/26/2010, Issue 606, p5 

    The article discusses research on the effectiveness of combined salmeterol/fluticasone propionate compared with salmeterol alone in the treatment of chronic obstructive pulmonary disease, referencing a study by A. A. Dalal presented at the 106th International Conference of the American Thoracic...

  • Effectiveness of Salmeterol in Treating COPD. Miller, Karl // American Family Physician;8/1/1999, Vol. 60 Issue 2, p628 

    Deals with a study that compared the safety and effectiveness of salmeterol with that of ipratropium and placebo in patients with chronic obstructive pulmonary disease. Materials; Methodology; Results; Conclusion; Implications.

  • Long-Acting β-Agonists With vs Without Inhaled Corticosteroids for COPD. Suissa, Samy; Ernst, Pierre // JAMA: Journal of the American Medical Association;1/20/2015, Vol. 313 Issue 3, p305 

    A letter to the editor is presented in response to an observational study led by Andrea S. Gershon, M.D., which evaluates the long-term outcomes linked with use of long-acting beta-agonists along with inhaled corticosteroids in chronic obstructive pulmonary disease.

  • ARCAPTA NEOHALER.  // Monthly Prescribing Reference;May2012, Vol. 28 Issue 5, pA-5 

    The article presents information on Arcapta Neohaler, the Indacaterol inhalation powder, from Novartis AG that is indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD). It provides information that the drug belongs to Long-acting beta2-agonist (LABA), a...

  • Management based on partnerships.  // New Zealand Doctor;11/19/2008, p23 

    The article discusses an asthma management plan based on partnerships. The goals of a successful management plan include minimal symptoms, minimal use of rescue medication, and promotion of normal or near-normal lung function. Among the medications that form the backbone of asthma therapy for...

  • Theravance Climbs as COPD Program Enters Phase III. Powers, Marie // BioWorld Today;2/4/2011, Vol. 22 Issue 24, p1 

    This article reports on a pair of clinical development programs focused on treatments for patients with chronic obstructive pulmonary disease (COPD) announced by GlaxoSmithKline PLC and Theravance Inc. in 2011. The two companies plan to conduct a Phase III program for the long-acting muscarinic...

  • INDACATEROL: A NEW APPROVED MOLECULE TO TREAT COPD. Jaithlia, Rajiv; Dev, Suresh Kr.; Gupta, Akash; Tanwar, Ravindra; Chouhan, Chetan // International Journal of Research in Ayurveda & Pharmacy;Sep2011, Vol. 2 Issue 5, p1518 

    Indacaterol approved as once-daily bronchodilator for chronic obstructive pulmonary disease (COPD). Indacaterol is a new molecular entity in the β2-adrenergic agonist class taken only once a day unlike the currently available β2-adrenergic agonist that helps relax muscles around lung...

  • Indacaterol the dominant option for COPD in Germany.  // PharmacoEconomics & Outcomes News;8/20/2011, Issue 635, p6 

    The article discusses a study which compared the cost effectiveness of indacaterol with tiotropium bromide and salmeterol in treating patients with chronic obstructive pulmonary disease (COPD) in Germany.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics